Lyell Immunopharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $929.8M | $293.8M |
| FY2022 | — | $833.3M | $123.6M |
| FY2023 | — | $655.0M | $145.6M |
| FY2024 | — | $382.8M | $105.6M |
| FY2025 | — | $248.2M | $60.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $929.8M | $293.8M |
| FY2022 | — | $833.3M | $123.6M |
| FY2023 | — | $655.0M | $145.6M |
| FY2024 | — | $382.8M | $105.6M |
| FY2025 | — | $248.2M | $60.2M |